Navigation Links
Novel Medical Device Patent Portfolio for Posterolateral Lumbar Disc Arthroplasty Offered for Sale by ICAP Patent Brokerage
Date:10/18/2011

CHICAGO, Oct. 18, 2011 /PRNewswire/ -- ICAP Patent Brokerage, a division of ICAP plc and the world's largest intellectual property brokerage and patent auction firm, is offering for sale a novel medical device patent portfolio related to the burgeoning field of Posterolateral Lumbar Disc Arthroplasty (PLDA). The portfolio includes a family of patents that covers both the device and methods of implantation.

(Logo:  http://photos.prnewswire.com/prnh/20100614/CG20517LOGO)

Developed and patented by Rush E. Simonson, a well-known and respected spinal industry executive, the medical device portfolio presents a surgical method for replacing damaged fibrocartilage between vertebrae in a patient's spine.  A commercial prototype related to this portfolio can be reviewed by interested parties under a non-disclosure agreement.

"This is an approach and technique which allows the surgeon the freedom to choose the best treatment option, and the ability to retain many key anatomical structures in the lumbar spine," commented the inventor Simonson.

Key attributes of the patented technology include:

  • Maintain and re-tension of the ALL, the PLL, and the annulus
  • Maintain the supraspinous ligament and interspinous ligaments
  • Unload the facets
  • Works with or without facets
  • Allows for hyper mobile segment
  • Accommodates various disc heights and stages of degeneration
  • Offers axial dampening and stress shielding to adjacent levels

As stated by Cameron Gray, ICAP Patent Brokerage Senior Vice President, "This portfolio is a key asset as the field of PLDA evolves. Market research suggests PLDA may well develop into a billion dollar industry in coming years, especially given its projected penetration into spinal surgical procedures."

To learn more about the assets available for license in this portfolio:

Contact Cameron Gray of ICAP Patent Brokerage at (650) 421-3089 or Cameron.Gray@us.icap.com.

About ICAP Patent Brokerage

ICAP Patent Brokerage is a division of ICAP plc and the world's largest intellectual property brokerage and patent auction firm.

About ICAP

ICAP is the world's premier interdealer broker and provider of post trade services. The Group matches buyers and sellers in the wholesale markets in interest rates, credit, commodities, foreign exchange, emerging markets, equities and equity derivatives through voice and electronic networks. ICAP plc was added to the FTSE 100 Index on 30 June 2006. For more information go to www.icap.com.


'/>"/>
SOURCE ICAP Patent Brokerage
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Novel Technology Breaks Through Cancer Pain
2. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
3. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
4. Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications to its RNAi Molecules
5. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
6. The Lancet Publishes Major Phase 3 Study on Novel Oral Direct Thrombin Inhibitor
7. Study Results for Aclidinium Bromide, a Novel Anticholinergic, Presented at European Respiratory Society Annual Congress
8. Phase 2 Clinical Studies Initiated for a Novel Therapeutic Candidate Identified Through Pharmacopeia Collaboration
9. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
10. ECLIPSE Data on Effects of Otsukas Investigational Novel Treatment, Tolvaptan, on Advanced Heart Failure Patients Hemodynamics and Urine Output Featured in Heart Failure Society of Americas Late Breaking Trials
11. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... -- Wells Specialty Pharmacy announces the acquisitions and merger of ... Winter Park, Florida and Pharm-EZ Medical, LLC, ... been consolidated into the 3796 Howell Branch Road Facility. ... Chad Tomlinson , former Vice President of Operations, has ... Tomlinson is a Graduate of Florida State University and has ...
(Date:1/19/2017)... LONDON , Jan. 19, 2017 ... 2022 Summary GlobalData,s new report, "Germany Cataract ... data on the Germany Cataract Surgery Devices market. The ... (in units) and average prices (USD) within market segements ... The report also provides company shares and distribution shares ...
(Date:1/19/2017)... YORK , Jan. 19, 2017 The ... provides understanding and access to partnering deals and agreements ... - Trends in partnering deals - Top deals by ... stage of development, technology type The report provides ... entered into by the world,s leading healthcare companies. ...
Breaking Medicine Technology:
(Date:1/20/2017)... ... January 20, 2017 , ... Source Vitál Apothecary, a skin and ... essential oils, announced the company had a successful visit to the 2017 ECRM Diet, ... gives companies that work in the nutritional, sports and health industries a chance to ...
(Date:1/20/2017)... ... January 20, 2017 , ... Bionic Sports Nutrition LLC, an American ... announced it had a successful January ECRM Trade Show in Hilton Head, SC. ... which allows it to provide its products to all clients at reasonable prices. At ...
(Date:1/20/2017)... ... January 20, 2017 , ... ... enhance people’s everyday lives, recently attended the January ECRM Trade Show in Hilton ... is known for its large range of supplements that keep the body functioning ...
(Date:1/20/2017)... ... 2017 , ... Michael and Betsy Brauser celebrated 5 years of Betsy’s participation ... trial has been life-saving as she has been on the trial for more ... diagnosed with ovarian cancer in 2009. She underwent standard chemotherapy but a year later ...
(Date:1/20/2017)... , ... January 20, 2017 , ... ... and its sugar-free alternative VW+ 002. The drinks have been produced in collaboration ... conditions to perform during your workout. , After a successful launch in Sweden ...
Breaking Medicine News(10 mins):